Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Terre Haute, Indiana Clinical Trials

A listing of Terre Haute, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (6) clinical trials

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers

The main purpose of the study is to compare treatment of non-infected venous leg ulcers using ICXP007 combined with four-layer compression bandaging, placebo combined with four-layer compression bandaging and four-layer compression bandaging alone.

Phase

0.75 miles

Learn More »

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB Stage IV or Recurrent Non-Small Cell Lung Cancer

OBJECTIVES: Primary - Compare the overall survival of patients with chemotherapy-naïve stage IIIB or IV or recurrent non-small cell lung cancer treated with paclitaxel poliglumex and carboplatin vs paclitaxel and carboplatin. Secondary - Compare the progression-free survival of women treated with these regimens. - Compare the disease control in women ...

Phase

4.17 miles

Learn More »

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.

Phase

4.17 miles

Learn More »

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

This open-label multicenter study will be conducted in 2 stages. Lead-in Phase: The first 6 patients treated will be evaluated to confirm the safety and feasibility of this regimen. After all 6 patients complete at least 4 weeks of treatment, and if no prohibitive toxicities are identified, continuous study treatment ...

Phase

4.17 miles

Learn More »

Patients should be in need of and fit for immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response, or progression within 6 months of the last course of treatment with a rituximab containing regimen). This study will be composed of two parts: Safety run-in and ...

Phase

4.17 miles

Learn More »